Top 5 Integration Mistakes Pharma CTOs Make (And How to Avoid Them)

Digital transformation in the pharmaceutical industry isn’t just about having separate tools; it’s also about how those tools work together. The glue is integration. But poor integration architecture often derails initiatives, delays launches, or opens up compliance risk or puts compliance at risk.

This blog talks about five common mistakes that CTOs make when they integrate digital systems and how to avoid them. We’ll look at real-life situations, come up with plans that can be put into action, and share lessons learnt from successful projects in the pharmaceutical and biotech industries.

Mistake 1: Spaghetti that goes from point to point

Connecting systems directly without a middleware strategy leads to a disarray of dependencies.

Every new system makes things ten times more complicated. For example, if you want to add a new field in Salesforce, you might need to update the code in four different systems, each of which is maintained by a different vendor.

One mid-sized pharma client used point-to-point XML file transfers between their CRM and ERP. After two acquisitions, changes in a product code field required 150+ hours of manual coordination.

Solution:

Use integration platforms 

Use service buses to send messages based on events.

Make interfaces the same (HL7/FHIR for health data, REST APIs)

Bonus Tip: We set up an integration catalogue as soon as possible. This makes it easy to see everything in one place and stops people from doing the same work twice.

Mistake 2: Not paying attention to GxP While Integrating

In life sciences, it’s very risky for integrations to skip validation until UAT.

Problem: Unchecked connections have the potential to disrupt the validated state of core systems. Missing paperwork during audits raises significant concerns.

Scenario: A PV system API update triggered unlogged data transformation in a downstream BI tool, violating Part 11 data integrity requirements.

Fix:

• Treat all integrations as GxP-impacting components
• Apply validation controls to middleware workflows, data pipelines, and scheduling mechanisms
• Document expected behavior, traceability matrices, and exception handling

Best Practice: Integrate CSV (Computer System Validation) deliverables directly into your SDLC. Don’t treat validation as an afterthought.

Mistake 3: Relying on Ad Hoc Data Mapping During Sprints

CTOs often rely on ad hoc mapping during sprints, especially for MVP builds.

Problem: Mismatches in field definitions, timestamps, or code sets lead to silent data corruption. Worse, they cause misinterpretations during regulatory reporting.

Fix:

• Define canonical data models for entities like HCPs, patients, and AEs
• Use controlled vocabularies (e.g., MedDRA, WHO Drug, SNOMED)
• Implement metadata registries and lineage tracking

Pro Tip: Tools like Collibra and Talend help maintain semantic consistency and stay aligned with evolving standards such as IDMP.

Mistake 4: Building Instead of Buying Middleware

The instinct to “just build a connector” is strong, especially under pressure.

Problem: Custom scripts are rarely future-proof. They often lack error handling, documentation, and auditability.

Fix:

• Explore iPaaS platforms including Informatica Cloud, Tray.io, and SnapLogic
• Prioritize vendors with out-of-the-box support for pharma systems like Veeva, SAP, and Oracle Argus
• Ensure GxP compatibility through documentation templates and sandbox environments

Guiding Principle: Build only when it delivers unique regulatory or operational advantage. Otherwise, buy.

Mistake 5: Treating Integration as a One-Time Effort

Many integration programs are project-led, not productised.

Problem: As platforms evolve, new endpoints are added, and APIs change versions, unmonitored integrations silently degrade or fail.

Fix:

• Establish integration as a product function with its own backlog and owners
• Implement proactive monitoring via Splunk, Datadog, or custom dashboards
• Revalidate and regression test integrations regularly

Success Metric: Mean Time to Detection (MTTD) for integration failures should be under 15 minutes for Tier 1 systems.

Newpage’s philosophy for integration is to have a modular, platform-agnostic architecture. 

• Connectors that are already built for Salesforce, Veeva, SAP, and CTMS GxP-compliant integration lifecycle from development to deployment. 
• Centralised governance and proactive error management

Our teams don’t just move data; they also make sure that the clinical, safety, and commercial ecosystems are all in line with compliance.

A Real-World Story: Enabling Digital Maturity at Scale

A global speciality pharma firm came to Newpage after failed integrations between their CRM and safety systems delayed a product launch.

Challenges:

• 7 custom interfaces with poor documentation
• 0 API monitoring
• No master data governance

Newpage Approach:

• Conducted an integration health check across 16 interfaces
• Replaced brittle scripts with MuleSoft orchestrations
• Centralized logging and alerting across three regions
• Added validation wrappers to ensure traceability

Results:

• API failure rates dropped 98%
• Cycle time for adverse event reporting improved by 40%
• Passed an unannounced regulatory audit with no integration-related findings

Integration Is Not a Backend Task. It’s a Strategic Layer.

Integration is like the blood flow in your digital business in the pharmaceutical industry. When done right, it gives you real-time information, speeds up regulatory processes, and lowers risk.

If you do it wrong, it turns into the hidden bottleneck that no one sees until it’s too late.

At Newpage, we help pharmaceutical CTOs build integration layers that are strong, tested, and ready for the future. This way, they can be sure that their digital investments will grow.